Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B

BACKGROUND: An international, multicenter extension study evaluated recombinant fusion protein linking recombinant coagulation factor IX (FIX) with recombinant human albumin (rIX‐FP) in hemophilia B (FIX ≤ 2%) patients previously enrolled in a phase III study or who initiated rIX‐FP prophylaxis foll...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Thromb Haemost
Egile Nagusiak: Mancuso, Maria Elisa, Lubetsky, Aaron, Pan‐Petesch, Brigitte, Lissitchkov, Toshko, Nagao, Azusa, Seifert, Wilfried, Li, Yanyan, Santagostino, Elena
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2020
Gaiak:
HAEMOSTASIS
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7318213/
https://ncbi.nlm.nih.gov/pubmed/32078256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jth.14778
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak